| Crizotinib studied in …STUDIED_INderived100 of 100show fewer |
|---|
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 100 trials list this drug (27 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02194738NA · active not recruiting Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) · 100 trials list this drug (27 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06140836Phase 3 · active not recruiting A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07816380Phase 3 · not yet recruiting A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04439253Phase 2 · active not recruiting Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) · 100 trials list this drug (27 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04693468Phase 1 · recruiting Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial · 100 trials list this drug (27 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07804186Phase 3 · recruiting Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma · 100 trials list this drug (27 active) | — | — | Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03375242completed Safety and Efficacy of Xalkori ROS1 · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04603807Phase 3 · active not recruiting A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02838420Phase 3 · completed A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) · 100 trials list this drug (27 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04084717Phase 2 · completed Study of Crizotinib for ROS1 and MET Activated Lung Cancer · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma,Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03194893Phase 3 · completed A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer · 100 trials list this drug (27 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03947385Phase 1/Phase 2 · recruiting Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions · 100 trials list this drug (27 active) | — | — | Cutaneous Melanoma,Uveal Melanoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02075840Phase 3 · completed A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06360575Phase 2 · active not recruiting Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) · 100 trials list this drug (27 active) | — | — | Lymphoma,Malignant Solid Neoplasm,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04439266Phase 2 · active not recruiting Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) · 100 trials list this drug (27 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02664935Phase 2 · completed National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer · 100 trials list this drug (27 active) | — | — | Adenocarcinoma,Squamous Cell Carcinoma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03737994Phase 2 · terminated Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer · 100 trials list this drug (27 active) | — | — | Malignant Lung Neoplasm,Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06563999Phase 2 · recruiting Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. · 100 trials list this drug (27 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06564324Phase 3 · recruiting A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05160922Phase 4 · active not recruiting Crizotinib Continuation Clinical Study · 100 trials list this drug (27 active) | — | — | Anaplastic Large Cell Lymphoma,Inflammatory Myofibroblastic Tumor,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03297606Phase 2 · recruiting Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) · 100 trials list this drug (27 active) | — | — | Solid Neoplasm,Multiple Myeloma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06357975Phase 2 · active not recruiting Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) · 100 trials list this drug (27 active) | — | — | Lymphoma,Malignant Solid Neoplasm,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04283669Phase 2 · completed Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas · 100 trials list this drug (27 active) | — | — | Vestibular Schwannoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05987332Phase 2/Phase 3 · active not recruiting IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma · 100 trials list this drug (27 active) | — | — | Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02201992Phase 3 · active not recruiting Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03052608Phase 3 · active not recruiting A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03620643Phase 2 · completed Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours · 100 trials list this drug (27 active) | — | — | Malignant Gastric Neoplasm,Breast Lobular Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02767804Phase 3 · active not recruiting eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04030429Phase 2 · terminated Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer · 100 trials list this drug (27 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06082635Phase 3 · active not recruiting TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC) · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05834348completed A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04423185Phase 2 · recruiting PLATFORM Study of Precision Medicine for Rare Tumors · 100 trials list this drug (27 active) | — | — | Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01121588Phase 1 · terminated Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK) · 100 trials list this drug (27 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02761057Phase 2 · completed Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed · 100 trials list this drug (27 active) | — | — | Papillary Renal Cell Carcinoma,Renal Cell Carcinoma,Type 1 Papillary Renal Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00828919NA · completed Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials · 100 trials list this drug (27 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03672643Phase 4 · terminated Long Term Safety Observation of Crizotinib in Chinese NSCLC Population · 100 trials list this drug (27 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04322890Phase 2 · recruiting Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05014464Phase 2 · recruiting ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01970865Phase 1/Phase 2 · completed A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02679170completed Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS) · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01712217Phase 1/Phase 2 · completed A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02473497no longer available Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients · 100 trials list this drug (27 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04322578Phase 2 · unknown Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01979536Phase 2 · completed Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma · 100 trials list this drug (27 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02034981Phase 2 · completed Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1 · 100 trials list this drug (27 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06254599Phase 3 · not yet recruiting A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02925234Phase 2 · recruiting The Drug Rediscovery Protocol (DRUP Trial) · 100 trials list this drug (27 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01606878Phase 1 · completed Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma · 100 trials list this drug (27 active) | — | — | Childhood Solid Neoplasm,Childhood Anaplastic Large Cell Lymphoma,Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03646994unknown Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03647111unknown Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01524926Phase 2 · completed CREATE: Cross-tumoral Phase 2 With Crizotinib · 100 trials list this drug (27 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02223819Phase 2 · completed Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy · 100 trials list this drug (27 active) | — | — | Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04632758Phase 3 · unknown Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02584634Phase 1/Phase 2 · terminated Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01744652Phase 1 · completed Dasatinib and Crizotinib in Advanced Cancer · 100 trials list this drug (27 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04647110completed Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers. · 100 trials list this drug (27 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02419287Phase 2 · completed Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas · 100 trials list this drug (27 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05725200Phase 2 · recruiting Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer · 100 trials list this drug (27 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00585195Phase 1 · completed A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer · 100 trials list this drug (27 active) | — | — | Systemic Anaplastic Large Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03574402Phase 2 · unknown Phase II Umbrella Study Directed by Next Generation Sequencing · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02612194Phase 2 · terminated LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer · 100 trials list this drug (27 active) | — | — | Bladder Neoplasm,Ureter Neoplasm,Urethra Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02183870Phase 2 · completed EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer · 100 trials list this drug (27 active) | — | — | Adenocarcinoma,Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02270034Phase 1 · completed Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma · 100 trials list this drug (27 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03088930Phase 2 · completed Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer · 100 trials list this drug (27 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05204628Phase 3 · unknown A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02207504Phase 1 · completed Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer · 100 trials list this drug (27 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01548144Phase 1 · terminated Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer · 100 trials list this drug (27 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02737501Phase 3 · completed ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants · 100 trials list this drug (27 active) | — | — | Carcinoma,Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02510001Phase 1 · completed MEK and MET Inhibition in Colorectal Cancer · 100 trials list this drug (27 active) | — | — | Solid Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02574078Phase 1/Phase 2 · completed A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04292119Phase 1/Phase 2 · unknown Lorlatinib Combinations in Lung Cancer · 100 trials list this drug (27 active) | — | — | Malignant Neoplasm,Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01945021Phase 2 · completed Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01531361Phase 1 · completed Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations · 100 trials list this drug (27 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01639001Phase 3 · completed A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01999972Phase 1 · completed A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors · 100 trials list this drug (27 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00939770Phase 1/Phase 2 · completed Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma · 100 trials list this drug (27 active) | — | — | Malignant Solid Neoplasm,Anaplastic Large Cell Lymphoma,Childhood Anaplastic Large Cell Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02638428Phase 2 · unknown Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy · 100 trials list this drug (27 active) | — | — | Childhood Solid Neoplasm,Childhood Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02134912Phase 2 · terminated S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib · 100 trials list this drug (27 active) | — | — | Lung Large Cell Carcinoma,Lung Non-Small Cell Carcinoma,Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04009317Phase 3 · unknown Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) · 100 trials list this drug (27 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01597258completed Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan) · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01822496Phase 2 · terminated Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02511184Phase 1 · terminated Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients · 100 trials list this drug (27 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01644773Phase 1 · completed Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) · 100 trials list this drug (27 active) | — | — | Diffuse Intrinsic Pontine Glioma,High-Grade Glioma, NOS | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03874273Phase 2/Phase 3 · unknown Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors · 100 trials list this drug (27 active) | — | — | Inflammatory Myofibroblastic Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01576406Phase 1 · completed Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients · 100 trials list this drug (27 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03707847Phase 4 · unknown Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL · 100 trials list this drug (27 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02836847Phase 2 · unknown Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma · 100 trials list this drug (27 active) | — | — | Gallbladder Neoplasm,Malignant Gallbladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01998126Phase 1 · completed Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02499614Phase 2 · unknown Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS) · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03085186no longer available Treatment With Crizotinib Single Patient Expanded Access IND 134375 · 100 trials list this drug (27 active) | — | — | Inflammatory Myofibroblastic Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02824094no longer available Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC · 100 trials list this drug (27 active) | — | — | Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02435108Phase 2 · completed A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy · 100 trials list this drug (27 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00932451Phase 2 · completed An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00932893Phase 3 · completed An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02487316Phase 4 · withdrawn A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib · 100 trials list this drug (27 active) | — | — | Systemic Anaplastic Large Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02277457early Phase 1 · withdrawn Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00965731Phase 1 · completed Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01121575Phase 1 · completed A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01500824Phase 2 · withdrawn A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer · 100 trials list this drug (27 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |